Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials. The study will further evaluate the safety and efficacy of T-1101 in patients with neuroendocrine tumors (NET), supporting the path toward future regulatory filings.   T-1101 is a first-in-class oral small-molecule inhibitor targeting Hec1/Nek2, designed to treat …

The 2025 ASCO Annual Meeting will be held from May 30 to June 3 in Chicago, USA. ASCO (American Society of Clinical Oncology) is the world’s largest and most authoritative clinical oncology meeting, bringing together many of the world’s leading oncology experts, and ASCO is an annual research event that publishes clinical oncology results from around the world. Taivex Therapeutics …

Taivex announced that the latest clinical trial data for its novel anticancer drug candidate T-1101 has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the world’s most prestigious oncology conferences, ASCO received over 7,500 abstract submissions this year. The selection of T-1101 underscores the innovation and clinical relevance of …

Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. This trial will further evaluate the safety and efficacy of T-1101 in patients with neuroendocrine tumors (NET), laying a solid foundation for future regulatory submissions.   T-1101 is the first-in-class oral small-molecule inhibitor targeting Hec1/Nek2, developed to treat …